Dr. Noronha has worked in the pharmaceutical industry for 14 years and has conducted clinical and nonclinical research in ophthalmology and oncology, including retinal diseases.
Previously, Dr. Noronha was the vice president of research and development at Sucampo Pharma Americas and chief scientific officer for JW Theriac.
The ophthalmic company develops commercial therapies for eye diseases.
More Articles on Ophthalmology:
Omeros Files Application for FDA Approval of Cataract Surgery Drug
Global Surgical Ophthalmology Market to be Worth $9B by 2017
United States Preventative Task Force Releases Uncertain Glaucoma Screening Recommendation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.